Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Valion BioVBIO +2.76%23 FCF Yield % is -854.32 as of Aug. 03, 2026. GuruFocus rates VBIO with a GF Score™ of 23/100. The stock has 1 warning sign investors should review. Among 1,410 Biotechnology companies, Valion Bio ranks worse than 98.79% on this metric.
FCF Yield % is calculated as Free Cash Flow divided by Market Capitalization. It is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.
Similar to Earnings Yield %, FCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high free cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.
Valion Bio FCF Yield % Related Terms
Valion Bio FCF Yield % Historical Data
* Premium members only.
The historical data trend for Valion Bio's FCF Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Valion Bio's FCF Yield %, along with its competitors' market caps and FCF Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Valion Bio FCF Yield % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Valion Bio's FCF Yield % distribution charts can be found below:
* The bar in red indicates where Valion Bio's FCF Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Valion Bio (VBIO) has a FCF Yield % of -854.32 as of Aug. 03, 2026. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on Valion Bio and its competitors. According to the industry distribution chart, Valion Bio ranks #1393 out of 1410 companies in the Biotechnology industry, placing it in the top 98.8%.
Is Valion Bio's FCF Yield % too high?
Valion Bio's current FCF Yield % is -854.32. Based on the distribution chart, Valion Bio ranks #1393 out of 1410 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Valion Bio has a GF Score™ of 23/100, reflecting its overall financial health beyond just this single metric.
How does Valion Bio's FCF Yield % compare to ZVSA and LYRA?
According to the Biotechnology industry distribution chart, Valion Bio ranks #1393 out of 1410 companies for FCF Yield %. This places Valion Bio in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Yield % for a Biotechnology company?
A good FCF Yield % depends on the Biotechnology industry context. However, FCF Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Yield % mean?
A high FCF Yield % can signal that a stock is expensive relative to its fundamentals. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on Valion Bio and its competitors. Valion Bio's current FCF Yield % is -854.32. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Valion Bio stock overvalued right now?
Valion Bio (VBIO) has a current FCF Yield % of -854.32. The current FCF Yield % is -854.32. Valion Bio's overall GF Score™ is 23/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Yield % calculated?
FCF Yield % is calculated from a company's financial statements. For Valion Bio (VBIO), the current FCF Yield % is -854.32 as of Aug. 03, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Valion Bio Inc is a late-stage biopharmaceutical company developing biologics that activate innate immune pathways for cytoprotection and immune modulation. Its main candidate, Entolimod, is a TLR5 agonist and also advances Entolasta, a next-generation TLR5 agonist, and targets the neutropenia oncology supportive care market.
23GF Score
Get the complete analysis for VBIO
FCF Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
VBIO has been successfully added to your 
